

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 3, 2010

**BECTON, DICKINSON AND COMPANY**

---

(Exact Name of Registrant as Specified in Its Charter)

**New Jersey**

---

(State or Other Jurisdiction of Incorporation)

**001-4802**

---

(Commission File Number)

**22-0760120**

---

(IRS Employer Identification No.)

**1 Becton Drive, Franklin Lakes, New Jersey**

---

(Address of Principal Executive Offices)

**07417-1880**

---

(Zip Code)

**(201) 847-6800**

---

(Registrant's Telephone Number, Including Area Code)

**N/A**

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**TABLE OF CONTENTS**

[ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION](#)

[ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS](#)

[SIGNATURES](#)

[Exhibit Index](#)

[EX-99.1](#)

[EX-99.2](#)

---

## [Table of Contents](#)

### ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 3, 2010, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its fourth fiscal quarter and fiscal year ending September 30, 2010. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”), as follows:

- **Revenues.** We present international and total revenue growth rates (for the total company and each of its business segments and units, and for our safety-engineered devices) after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that this allows investors to better understand the underlying operating results of BD and facilitates comparisons to prior periods.
- **Earnings Per Share from Continuing Operations** We present our diluted earnings per share from continuing operations (“EPS”) for fiscal year 2010 after eliminating the non-cash charge related to health care reform impacting Medicare Part D reimbursements. We also present our EPS for fiscal year 2009 after excluding the tax benefit relating to various tax settlements and the impact of the charge relating to our pending settlement of certain antitrust class action suits. These items are not considered by management to be part of ordinary operations. Accordingly, we believe that these adjusted measures of EPS are more indicative of BD’s underlying performance for these periods, and allows investors to more easily compare BD’s performance for these periods.

We also present our growth in EPS for the fourth quarter of fiscal year 2010, and in adjusted EPS for fiscal year 2010, after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD, and facilitates comparisons to the prior year periods.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

---

[Table of Contents](#)

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated November 3, 2010, which is furnished pursuant to Item 2.02

Exhibit 99.2 Reconciliation of non-GAAP financial measures, which is furnished pursuant to Item 2.02

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Dean J. Parnicas  
Dean J. Parnicas  
Vice President, Corporate  
Secretary and Public Policy

Date: November 3, 2010

---

[Table of Contents](#)

Exhibit Index

- 99.1 Press release dated November 3, 2010, which is furnished pursuant to Item 2.02
- 99.2 Reconciliation of non-GAAP financial measures, which is furnished pursuant to Item 2.02

1 Becton Drive  
Franklin Lakes, NJ 07417  
www.bd.com

News Release



Contact:

Zachary A. Nagle, Investor Relations — 201-847-5453  
Colleen T. White, Corporate Communications — 201-847-5369

**BD ANNOUNCES RESULTS FOR 2010 FOURTH FISCAL QUARTER AND FULL YEAR**

- Reports diluted earnings per share from continuing operations of \$1.24 for the fourth quarter and \$4.90 for the full fiscal year, in line with the Company's expectations.
- States that reported earnings reflect the reclassification of the operating results and gain on the sale of the Ophthalmic Systems unit and certain platforms of the Medical Surgical Systems unit as discontinued operations.
- Announces planned stock repurchases of \$1.5 billion in 2011 funded by ongoing cash flow and the issuance of debt.
- Expects full fiscal year 2011 diluted earnings per share from continuing operations to be between \$5.45 and \$5.55, an increase of 11 to 13 percent on an as-reported basis.

**Franklin Lakes, NJ (November 3, 2010)**— BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of \$1.873 billion for the fourth fiscal quarter ended September 30, 2010, representing an increase of 1.0 percent from the prior-year period, or 2.9 percent on a foreign currency-neutral basis.

---

For the full fiscal year ended September 30, 2010, BD reported revenues of \$7.372 billion, representing an increase of 5.5 percent over the prior year, or 5.6 percent on a foreign currency-neutral basis.

The Company also plans to repurchase \$1.5 billion of its common stock in 2011 and an additional \$600 million in 2012. The Company plans to fund the repurchases through ongoing cash flow and the issuance of debt.

“We are proud of our accomplishments during 2010. We met our financial and operational goals despite the challenging macroeconomic climate facing our industry,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “Our solid performance has enabled us to continue to return significant value to shareholders and also to invest in key geographic expansion, new product platforms and businesses and operational excellence programs. We have confidence in our outlook for fiscal year 2011 and remain committed to serving our customers with superior healthcare products.”

**Update on the Sale of Certain Assets in the BD Medical Segment**

In the fourth quarter of fiscal year 2010, the Company completed the sale of the Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms. The results of operations associated with the Ophthalmic Systems unit, surgical blade platform and critical care platform have been reclassified as discontinued operations for all quarters and years referred to in this release.

---



As illustrated on page 3 of the attached financial tables, diluted earnings per share from discontinued operations for the fourth quarter of \$0.44 consisted of \$0.06 from operations and \$0.39 from the gain on the sale. Diluted earnings per share for the fourth quarter of \$1.68 less the \$0.44 from discontinued operations resulted in diluted earnings per share from continuing operations of \$1.24. Diluted earnings per share from discontinued operations for the year of \$0.59 consisted of \$0.21 from operations and \$0.38 from the gain on the sale. Diluted earnings per share for the year of \$5.49 less the \$0.59 from discontinued operations resulted in diluted earnings per share from continuing operations of \$4.90.

Also included in the attached financial tables are the Company's Consolidated Income Statements for the first three quarters of fiscal year 2010 and for all periods in fiscal year 2009 for reference, which reflect the reclassification change for the Ophthalmic Systems unit, surgical blade platform and critical care platform. The results of operations associated with the extended dwell catheter product platform are reported within continuing operations, as this asset group did not meet the criteria for discontinued operations.

**Fourth Quarter Earnings and Analysis of the Full Fiscal Year 2010 and 2009 Earnings**

Reported diluted earnings per share from continuing operations for the fourth quarter were \$1.24, compared with \$1.20 in the prior-year period, representing a 3.3 percent increase. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fourth quarter increased by 1.7 percent.

---

For the full fiscal year ended September 30, 2010, reported diluted earnings per share from continuing operations were \$4.90, compared with \$4.73 in the prior fiscal year, representing an increase of 3.6 percent. Current full fiscal year results include a previously disclosed non-cash charge of \$8.9 million, or \$0.04 per share from continuing operations, related to healthcare reform impacting Medicare Part D reimbursements. The prior fiscal year included a \$20 million, or \$0.08 per share, tax benefit related to various tax settlements in multiple jurisdictions and a litigation charge of \$45 million, or \$0.11 per share, which were also previously disclosed. Excluding these items, adjusted diluted earnings per share from continuing operations increased by 3.8 percent to \$4.94, compared with \$4.76 adjusted diluted earnings per share in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fiscal year increased 9.2 percent.

#### **Segment Results**

In the BD Medical segment, worldwide revenues for the quarter were \$959 million, representing a decrease of 0.3 percent compared with the prior-year period. Revenues increased 2.1 percent on a foreign currency-neutral basis. Segment revenue growth reflected an unfavorable comparison to the prior year of 4.3 percentage points due to the sales related to the H1N1 flu pandemic in fiscal year 2009, partially offset by strong growth in the Diabetes Care business. For the twelve-month period ended September 30, 2010, BD Medical revenues increased 6.7 percent, or 6.2 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$591 million, representing an increase of 2.0 percent compared with the prior-year period, or 3.1 percent on a foreign currency-neutral basis. Segment revenue growth was negatively impacted by 2.4 percentage points due to sales

---

related to the flu pandemic in fiscal year 2009 in addition to lower lab testing and reduced physician office visits. For the twelve-month period ended September 30, 2010, BD Diagnostics revenues increased 4.2 percent, or 4.0 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$323 million, representing an increase of 3.5 percent compared with the prior-year period. Revenues increased 5.3 percent on a foreign currency-neutral basis, primarily driven by instrument and reagent sales in the Cell Analysis business unit. For the twelve-month period ended September 30, 2010, BD Biosciences revenues increased 4.4 percent, or 6.8 percent on a foreign currency-neutral basis.

#### **Geographic Results**

Fourth quarter revenues in the U.S. were \$832 million, representing an increase of 1.4 percent compared with the prior-year period, including a negative impact of 1.8 percentage points related to the flu pandemic. Revenues outside of the U.S. were \$1.041 billion, representing an increase of 0.8 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. International revenue growth was negatively impacted by 4 percentage points due to the H1N1 flu pandemic-related sales in fiscal year 2009. Revenues reflected continuing strength in emerging markets, which was partially offset by slower growth in Europe. For the twelve-month period ended September 30, 2010, revenues in the U.S. were \$3.287 billion, representing an increase of 5.0 percent compared with the prior-year period. Revenues outside of the U.S. were \$4.086 billion, representing an increase of 5.9 percent compared with the prior-year period, or 6.0 percent on a foreign currency-neutral basis.

---

### **Fiscal 2011 Outlook for Full Year**

The Company estimates that reported revenues for the full fiscal year 2011 will increase about 4 percent. The Company also expects reported diluted earnings per share from continuing operations for fiscal year 2011 to be between \$5.45 and \$5.55, an increase of approximately 11 to 13 percent over fiscal year 2010. Diluted earnings per share from continuing operations for fiscal year 2011 are expected to increase 10 to 12 percent over adjusted diluted earnings per share from continuing operations, excluding specified item, of \$4.94 for the fiscal year 2010.

### **Conference Call Information**

A conference call regarding BD's fourth quarter results and its expectations for the full fiscal year 2011 will be broadcast live on BD's website, [www.bd.com/investors](http://www.bd.com/investors), along with related slides, at 10:00 a.m. (ET) Thursday, November 4, 2010. The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on Thursday, November 11, 2010, access code 15660232.

### **Non-GAAP Financial Measures**

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables and the Form 8-K that BD filed today with the SEC.

### **About BD**

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of

---

diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit [www.bd.com](http://www.bd.com).

\*\*\*

*This press release, including the section entitled "Fiscal 2011 Outlook", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.*

---

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	2010	Three Months Ended September 30, 2009	% Change
REVENUES	\$1,873,195	\$1,854,023	1.0
Cost of products sold	900,933	890,197	1.2
Selling and administrative	438,139	427,008	2.6
Research and development	123,606	112,890	9.5
<b>TOTAL OPERATING COSTS AND EXPENSES</b>	<b>1,462,678</b>	<b>1,430,095</b>	<b>2.3</b>
OPERATING INCOME	410,517	423,928	(3.2)
Interest income	14,594	14,418	1.2
Interest expense	(12,278)	(13,782)	(10.9)
Other income (expense), net	1,285	(3,312)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	414,118	421,252	(1.7)
Income tax provision	121,065	126,824	(4.5)
INCOME FROM CONTINUING OPERATIONS	293,053	294,428	(0.5)
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$27,645 AND \$7,684, RESPECTIVELY	103,642	22,792	NM
NET INCOME	\$ 396,695	\$ 317,220	25.1
<b>EARNINGS PER SHARE</b>			
Basic:			
Income from continuing operations	\$ 1.27	\$ 1.23	3.3
Income from discontinued operations	\$ 0.45	\$ 0.10	NM
Net income (1)	\$ 1.71	\$ 1.33	28.6
Diluted:			
Income from continuing operations	\$ 1.24	\$ 1.20	3.3
Income from discontinued operations	\$ 0.44	\$ 0.09	NM
Net income	\$ 1.68	\$ 1.29	30.2
<b>AVERAGE SHARES OUTSTANDING</b>			
Basic	231,396	239,162	
Diluted	236,316	245,056	

NM — Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	2010	Twelve Months Ended September 30, 2009	% Change
REVENUES	\$7,372,333	\$6,986,722	5.5
Cost of products sold	3,543,183	3,311,676	7.0
Selling and administrative	1,721,356	1,680,797	2.4
Research and development	430,997	404,567	6.5
TOTAL OPERATING COSTS AND EXPENSES	5,695,536	5,397,040	5.5
OPERATING INCOME	1,676,797	1,589,682	5.5
Interest income	35,129	33,148	6.0
Interest expense	(51,263)	(40,389)	26.9
Other income (expense), net	497	(3,850)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,661,160	1,578,591	5.2
Income tax provision	484,820	411,246	17.9
INCOME FROM CONTINUING OPERATIONS	1,176,340	1,167,345	0.8
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$40,703 AND \$19,975, RESPECTIVELY	141,270	64,258	NM
NET INCOME	\$1,317,610	\$1,231,603	7.0
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 5.02	\$ 4.85	3.5
Income from discontinued operations	\$ 0.60	\$ 0.27	NM
Net income	\$ 5.62	\$ 5.12	9.8
Diluted:			
Income from continuing operations	\$ 4.90	\$ 4.73	3.6
Income from discontinued operations	\$ 0.59	\$ 0.26	NM
Net income	\$ 5.49	\$ 4.99	10.0
AVERAGE SHARES OUTSTANDING			
Basic	234,328	240,479	
Diluted	240,136	246,798	

NM — Not Meaningful

Becton Dickinson and Company  
 Supplemental Income Statement Information — Fiscal 2010  
 Revised for discontinued operations of certain Medical segment divestitures  
 (Unaudited: Amounts in thousands, except per-share data)

	Previously Reported	Amounts Reclassified to Discontinued Operations	As Revised	
<b>Quarter 1</b>				
Revenues	\$ 1,916,774	\$ 47,956	\$ 1,868,818	
Income from Continuing Operations	\$ 315,978	\$ 11,885	\$ 304,093	
Diluted Earnings Per Share from Continuing Operations	\$ 1.30	\$ 0.05	\$ 1.25	
<b>Quarter 2</b>				
Revenues	\$ 1,844,854	\$ 45,445	\$ 1,799,409	
Income from Continuing Operations	\$ 297,725	\$ 12,691	\$ 285,034	
Diluted Earnings Per Share from Continuing Operations (2)	\$ 1.24	\$ 0.05	\$ 1.18	
<b>Quarter 3</b>				
Revenues	\$ 1,878,229	\$ 47,318	\$ 1,830,911	
Income from Continuing Operations	\$ 306,283	\$ 12,123	\$ 294,160	
Diluted Earnings Per Share from Continuing Operations (2)	\$ 1.29	\$ 0.05	\$ 1.23	
	Amounts Reclassified to Discontinued Operations			From Continuing Operations
	Total	Operations Excluding Gain	Gain on Sale	Total
<b>Quarter 4 (1)</b>				
Revenues	\$ 1,899,548	\$ 26,353	\$ —	\$ 26,353
Income	\$ 397,445	\$ 13,258	\$ 91,134	\$ 104,392
Diluted Earnings Per Share (2)	\$ 1.68	\$ 0.06	\$ 0.39	\$ 0.44
<b>Year (1)</b>				
Revenues	\$ 7,539,405	\$ 167,072	\$ —	\$ 167,072
Income	\$ 1,317,431	\$ 49,957	\$ 91,134	\$ 141,091
Diluted Earnings Per Share	\$ 5.49	\$ 0.21	\$ 0.38	\$ 0.59

Certain quarterly amounts may not add to the year-to-date totals due to rounding.

- (1) The sale of Ophthalmic Systems unit and the surgical blades product platforms was completed on July 30, 2010 and the sale of the critical care product platform was completed on September 30, 2010.
- (2) Diluted Earnings Per Share may not add due to rounding.



Becton Dickinson and Company  
 Supplemental Income Statement Information — Fiscal 2009 and 2008  
 Revised for discontinued operations of certain Medical segment divestitures  
 (Unaudited: Amounts in thousands, except per-share data)

	Previously Reported	Amounts Reclassified to Discontinued Operations	As Revised
<b>Fiscal 2009</b>			
Revenues	\$7,160,874	\$ 174,152	\$6,986,722
Income from Continuing Operations	\$1,213,054	\$ 45,709	\$1,167,345
Diluted Earnings Per Share from Continuing Operations	\$ 4.92	\$ 0.19	\$ 4.73
<b>Fiscal 2008</b>			
Revenues	\$7,074,942	\$ 177,323	\$6,897,619
Income from Continuing Operations	\$1,115,867	\$ 38,113	\$1,077,754
Diluted Earnings Per Share from Continuing Operations	\$ 4.42	\$ 0.15	\$ 4.27

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	2010	Three Months Ended September 30, 2009	% Change
<b>BD MEDICAL</b>			
United States	\$ 400,231	\$ 392,111	2.1
International	558,374	569,677	(2.0)
<b>TOTAL</b>	<b>\$ 958,605</b>	<b>\$ 961,788</b>	<b>(0.3)</b>
<b>BD DIAGNOSTICS</b>			
United States	\$ 307,721	\$ 305,488	0.7
International	283,743	274,521	3.4
<b>TOTAL</b>	<b>\$ 591,464</b>	<b>\$ 580,009</b>	<b>2.0</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 124,009	\$ 123,225	0.6
International	199,117	189,001	5.4
<b>TOTAL</b>	<b>\$ 323,126</b>	<b>\$ 312,226</b>	<b>3.5</b>
<b>TOTAL REVENUES</b>			
United States	\$ 831,961	\$ 820,824	1.4
International	1,041,234	1,033,199	0.8
<b>TOTAL</b>	<b>\$1,873,195</b>	<b>\$1,854,023</b>	<b>1.0</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	Twelve Months Ended September 30,		
	2010	2009	% Change
<b>BD MEDICAL</b>			
United States	\$1,596,336	\$1,503,471	6.2
International	2,200,096	2,053,223	7.2
<b>TOTAL</b>	<b>\$3,796,432</b>	<b>\$3,556,694</b>	<b>6.7</b>
<b>BD DIAGNOSTICS</b>			
United States	\$1,214,288	\$1,177,543	3.1
International	1,104,591	1,048,676	5.3
<b>TOTAL</b>	<b>\$2,318,879</b>	<b>\$2,226,219</b>	<b>4.2</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 475,941	\$ 449,151	6.0
International	781,081	754,658	3.5
<b>TOTAL</b>	<b>\$1,257,022</b>	<b>\$1,203,809</b>	<b>4.4</b>
<b>TOTAL REVENUES</b>			
United States	\$3,286,565	\$3,130,165	5.0
International	4,085,768	3,856,557	5.9
<b>TOTAL</b>	<b>\$7,372,333</b>	<b>\$6,986,722</b>	<b>5.5</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended September 30,  
(Unaudited; Amounts in thousands)

	United States		% Change
	2010	2009	
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$256,290	\$255,168	0.4
Diabetes Care	98,633	88,590	11.3
Pharmaceutical Systems	45,308	48,353	(6.3)
<b>TOTAL</b>	<b>\$400,231</b>	<b>\$392,111</b>	<b>2.1</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$162,024	\$156,328	3.6
Diagnostic Systems	145,697	149,160	(2.3)
<b>TOTAL</b>	<b>\$307,721</b>	<b>\$305,488</b>	<b>0.7</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 86,765	\$ 84,179	3.1
Discovery Labware	37,244	39,046	(4.6)
<b>TOTAL</b>	<b>\$124,009</b>	<b>\$123,225</b>	<b>0.6</b>
<b>TOTAL UNITED STATES</b>	<b>\$831,961</b>	<b>\$820,824</b>	<b>1.4</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

	International				
	2010	2009	Reported	% Change	
				FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 245,724	\$ 253,384	(3.0)	(2.2)	(0.8)
Diabetes Care	100,468	92,098	9.1	12.0	(2.9)
Pharmaceutical Systems	212,182	224,195	(5.4)	2.8	(8.2)
<b>TOTAL</b>	<b>\$ 558,374</b>	<b>\$ 569,677</b>	<b>(2.0)</b>	<b>2.1</b>	<b>(4.1)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 144,421	\$ 138,297	4.4	7.4	(3.0)
Diagnostic Systems	139,322	136,224	2.3	4.1	(1.8)
<b>TOTAL</b>	<b>\$ 283,743</b>	<b>\$ 274,521</b>	<b>3.4</b>	<b>5.7</b>	<b>(2.3)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 160,230	\$ 150,055	6.8	10.4	(3.6)
Discovery Labware	38,887	38,946	(0.2)	0.8	(1.0)
<b>TOTAL</b>	<b>\$ 199,117</b>	<b>\$ 189,001</b>	<b>5.4</b>	<b>8.4</b>	<b>(3.0)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$1,041,234</b>	<b>\$1,033,199</b>	<b>0.8</b>	<b>4.2</b>	<b>(3.4)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

	2010	2009	Total		
			Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 502,014	\$ 508,552	(1.3)	(0.9)	(0.4)
Diabetes Care	199,101	180,688	10.2	11.7	(1.5)
Pharmaceutical Systems	257,490	272,548	(5.5)	1.2	(6.7)
<b>TOTAL</b>	<b>\$ 958,605</b>	<b>\$ 961,788</b>	<b>(0.3)</b>	<b>2.1</b>	<b>(2.4)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 306,445	\$ 294,625	4.0	5.4	(1.4)
Diagnostic Systems	285,019	285,384	(0.1)	0.7	(0.8)
<b>TOTAL</b>	<b>\$ 591,464</b>	<b>\$ 580,009</b>	<b>2.0</b>	<b>3.1</b>	<b>(1.1)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 246,995	\$ 234,234	5.4	7.8	(2.4)
Discovery Labware	76,131	77,992	(2.4)	(1.9)	(0.5)
<b>TOTAL</b>	<b>\$ 323,126</b>	<b>\$ 312,226</b>	<b>3.5</b>	<b>5.3</b>	<b>(1.8)</b>
<b>TOTAL REVENUES</b>	<b>\$1,873,195</b>	<b>\$1,854,023</b>	<b>1.0</b>	<b>2.9</b>	<b>(1.9)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Twelve Months Ended September 30,  
(Unaudited; Amounts in thousands)

	United States		% Change
	2010	2009	
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$1,007,322	\$ 974,324	3.4
Diabetes Care	383,783	351,618	9.1
Pharmaceutical Systems	205,231	177,529	15.6
<b>TOTAL</b>	<b>\$1,596,336</b>	<b>\$1,503,471</b>	<b>6.2</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 627,421	\$ 608,754	3.1
Diagnostic Systems	586,867	568,789	3.2
<b>TOTAL</b>	<b>\$1,214,288</b>	<b>\$1,177,543</b>	<b>3.1</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 326,916	\$ 303,846	7.6
Discovery Labware	149,025	145,305	2.6
<b>TOTAL</b>	<b>\$ 475,941</b>	<b>\$ 449,151</b>	<b>6.0</b>
<b>TOTAL UNITED STATES</b>	<b>\$3,286,565</b>	<b>\$3,130,165</b>	<b>5.0</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Twelve Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

	International				
	2010	2009	Reported	% Change	
				FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$1,002,687	\$ 914,990	9.6	6.6	3.0
Diabetes Care	401,976	363,319	10.6	9.1	1.5
Pharmaceutical Systems	795,433	774,914	2.6	4.3	(1.7)
<b>TOTAL</b>	<b>\$2,200,096</b>	<b>\$2,053,223</b>	<b>7.2</b>	<b>6.2</b>	<b>1.0</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 570,386	\$ 534,677	6.7	5.8	0.9
Diagnostic Systems	534,205	513,999	3.9	3.9	—
<b>TOTAL</b>	<b>\$1,104,591</b>	<b>\$1,048,676</b>	<b>5.3</b>	<b>4.9</b>	<b>0.4</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 624,322	\$ 600,671	3.9	7.9	(4.0)
Discovery Labware	156,759	153,987	1.8	4.5	(2.7)
<b>TOTAL</b>	<b>\$ 781,081</b>	<b>\$ 754,658</b>	<b>3.5</b>	<b>7.2</b>	<b>(3.7)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$4,085,768</b>	<b>\$3,856,557</b>	<b>5.9</b>	<b>6.0</b>	<b>(0.1)</b>



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Twelve Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

	2010	2009	Total		
			Reported	% Change	
				FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$2,010,009	\$1,889,314	6.4	4.9	1.5
Diabetes Care	785,759	714,937	9.9	9.1	0.8
Pharmaceutical Systems	1,000,664	952,443	5.1	6.4	(1.3)
<b>TOTAL</b>	<b>\$3,796,432</b>	<b>\$3,556,694</b>	<b>6.7</b>	<b>6.2</b>	<b>0.5</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$1,197,807	\$1,143,431	4.8	4.4	0.4
Diagnostic Systems	1,121,072	1,082,788	3.5	3.5	—
<b>TOTAL</b>	<b>\$2,318,879</b>	<b>\$2,226,219</b>	<b>4.2</b>	<b>4.0</b>	<b>0.2</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 951,238	\$ 904,517	5.2	7.8	(2.6)
Discovery Labware	305,784	299,292	2.2	3.6	(1.4)
<b>TOTAL</b>	<b>\$1,257,022</b>	<b>\$1,203,809</b>	<b>4.4</b>	<b>6.8</b>	<b>(2.4)</b>
<b>TOTAL REVENUES</b>	<b>\$7,372,333</b>	<b>\$6,986,722</b>	<b>5.5</b>	<b>5.6</b>	<b>(0.1)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
SAFETY REVENUES  
(Unaudited; Amounts in thousands)

	Three Months Ended September 30,				
	2010	2009	Reported	% Change FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$282,968	\$276,409	2.4	2.4	—
International	160,396	150,270	6.7	9.2	(2.5)
<b>TOTAL</b>	<b>\$443,364</b>	<b>\$426,679</b>	<b>3.9</b>	<b>4.8</b>	<b>(0.9)</b>
<b>BY SEGMENT</b>					
BD Medical	\$208,822	\$204,536	2.1	2.7	(0.6)
BD Diagnostics	234,542	222,143	5.6	6.7	(1.1)
<b>TOTAL</b>	<b>\$443,364</b>	<b>\$426,679</b>	<b>3.9</b>	<b>4.8</b>	<b>(0.9)</b>

	Twelve Months Ended September 30,				
	2010	2009	Reported	% Change FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$1,108,431	\$1,056,797	4.9	4.9	—
International	621,913	568,106	9.5	8.1	1.4
<b>TOTAL</b>	<b>\$1,730,344</b>	<b>\$1,624,903</b>	<b>6.5</b>	<b>6.0</b>	<b>0.5</b>
<b>BY SEGMENT</b>					
BD Medical	\$ 819,084	\$ 761,262	7.6	6.9	0.7
BD Diagnostics	911,260	863,641	5.5	5.2	0.3
<b>TOTAL</b>	<b>\$1,730,344</b>	<b>\$1,624,903</b>	<b>6.5</b>	<b>6.0</b>	<b>0.5</b>

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS FISCAL 2010  
Revised for discontinued operations of certain Medical segment divestitures  
(Unaudited; Amounts in thousands, except per-share data)

	Quarter 1	Quarter 2	Quarter 3	Quarter 3 YTD
REVENUES	\$ 1,868,818	\$ 1,799,409	\$ 1,830,911	\$ 5,499,138
Cost of products sold	894,324	864,492	883,434	2,642,250
Selling and administrative	445,673	421,076	416,468	1,283,217
Research and development	99,151	100,193	108,047	307,391
<b>TOTAL OPERATING COSTS AND EXPENSES</b>	<b>1,439,148</b>	<b>1,385,761</b>	<b>1,407,949</b>	<b>4,232,858</b>
OPERATING INCOME	429,670	413,648	422,962	1,266,280
Interest income	8,789	9,652	2,094	20,535
Interest expense	(12,987)	(12,913)	(13,085)	(38,985)
Other (expense) income, net	(2,354)	164	1,402	(788)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	423,118	410,551	413,373	1,247,042
Income tax provision	119,025	125,517	119,213	363,755
INCOME FROM CONTINUING OPERATIONS	304,093	285,034	294,160	883,287
Income from Discontinued Operations before Income Tax	16,900	16,698	17,088	50,686
Income Tax provision	4,617	4,101	4,340	13,058
INCOME FROM DISCONTINUED OPERATIONS	12,283	12,597	12,748	37,628
NET INCOME	\$ 316,376	\$ 297,631	\$ 306,908	920,915
<b>EARNINGS PER SHARE</b>				
Basic:				
Income from continuing operations	\$ 1.28	\$ 1.21	\$ 1.26	\$ 3.75
Income from discontinued operations	\$ 0.05	\$ 0.05	\$ 0.05	\$ 0.16
Net income (1)	\$ 1.33	\$ 1.26	\$ 1.32	\$ 3.91
Diluted:				
Income from continuing operations	\$ 1.25	\$ 1.18	\$ 1.23	\$ 3.66
Income from discontinued operations	\$ 0.05	\$ 0.05	\$ 0.05	\$ 0.16
Net income (1)	\$ 1.30	\$ 1.24	\$ 1.29	\$ 3.82
<b>AVERAGE SHARES OUTSTANDING</b>				
Basic	237,360	235,325	233,242	235,316
Diluted	242,965	240,863	238,319	241,151

Certain quarterly amounts may not add to the year-to-date totals due to rounding.

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS FISCAL 2009  
Revised for discontinued operations of certain Medical segment divestitures  
(Unaudited; Amounts in thousands, except per-share data)

	Quarter 1	Quarter 2	Quarter 3	Quarter 4	Year
REVENUES	\$1,673,148	\$1,683,142	\$1,776,409	\$1,854,023	\$6,986,722
Cost of products sold	775,542	807,382	838,555	890,197	3,311,676
Selling and administrative	399,668	430,608	423,513	427,008	1,680,797
Research and development	96,356	97,700	97,621	112,890	404,567
<b>TOTAL OPERATING COSTS AND EXPENSES</b>	<b>1,271,566</b>	<b>1,335,690</b>	<b>1,359,689</b>	<b>1,430,095</b>	<b>5,397,040</b>
OPERATING INCOME	401,582	347,452	416,720	423,928	1,589,682
Interest income	1,651	4,312	12,767	14,418	33,148
Interest expense	(7,824)	(7,495)	(11,288)	(13,782)	(40,389)
Other income (expense), net	9,411	(5,701)	(4,246)	(3,312)	(3,850)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	404,820	338,568	413,953	421,252	1,578,591
Income tax provision	108,213	89,702	86,508	126,824	411,246
INCOME FROM CONTINUING OPERATIONS	296,607	248,866	327,445	294,428	1,167,345
Income from Discontinued Operations before Income Tax	20,234	15,944	17,579	30,476	84,233
Income Tax provision	4,773	3,521	3,997	7,684	19,975
INCOME FROM DISCONTINUED OPERATIONS	15,461	12,423	13,582	22,792	64,258
NET INCOME	\$ 312,068	\$ 261,289	\$ 341,027	\$ 317,220	\$1,231,603
<b>EARNINGS PER SHARE</b>					
Basic:					
Income from continuing operations	\$ 1.22	\$ 1.04	\$ 1.36	\$ 1.23	\$ 4.85
Income from discontinued operations	\$ 0.06	\$ 0.05	\$ 0.06	\$ 0.10	\$ 0.27
Net income (1)	\$ 1.29	\$ 1.09	\$ 1.42	\$ 1.33	\$ 5.12
Diluted:					
Income from continuing operations	\$ 1.19	\$ 1.01	\$ 1.33	\$ 1.20	\$ 4.73
Income from discontinued operations	\$ 0.06	\$ 0.05	\$ 0.06	\$ 0.09	\$ 0.26
Net income (1)	\$ 1.26	\$ 1.06	\$ 1.39	\$ 1.29	\$ 4.99
<b>AVERAGE SHARES OUTSTANDING</b>					
Basic	242,397	240,239	240,109	239,162	240,479
Diluted	248,311	245,890	245,696	245,056	246,798

Certain quarterly amounts may not add to the year-to-date totals due to rounding.

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 SAFETY REVENUES FISCAL 2010  
 Revised for discontinued operations of certain Medical segment divestitures  
 (Unaudited; Amounts in thousands)

	Quarter 1	Quarter 2	Quarter 3	Quarter 3 YTD
<b>TOTAL SAFETY REVENUES</b>				
United States	\$291,815	\$263,044	\$270,604	\$ 825,463
International	155,129	148,537	157,851	461,517
<b>TOTAL</b>	<b>\$446,944</b>	<b>\$411,581</b>	<b>\$428,455</b>	<b>\$1,286,980</b>
<b>BY SEGMENT</b>				
BD Medical	\$221,174	\$193,688	\$195,400	\$ 610,262
BD Diagnostics	225,770	217,893	233,055	676,718
<b>TOTAL</b>	<b>\$446,944</b>	<b>\$411,581</b>	<b>\$428,455</b>	<b>\$1,286,980</b>

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 SAFETY REVENUES FISCAL 2009  
 Revised for discontinued operations of certain Medical segment divestitures  
 (Unaudited; Amounts in thousands)

	Quarter 1	Quarter 2	Quarter 3	Quarter 4	Year
<b>TOTAL SAFETY REVENUES</b>					
United States	\$263,865	\$249,820	\$266,703	\$276,409	\$1,056,797
International	133,499	136,054	148,283	150,270	568,106
<b>TOTAL</b>	<b>\$397,364</b>	<b>\$385,874</b>	<b>\$414,986</b>	<b>\$426,679</b>	<b>\$1,624,903</b>
<b>BY SEGMENT</b>					
BD Medical	\$187,066	\$177,721	\$191,939	\$204,536	\$ 761,262
BD Diagnostics	210,298	208,153	223,047	222,143	863,641
<b>TOTAL</b>	<b>\$397,364</b>	<b>\$385,874</b>	<b>\$414,986</b>	<b>\$426,679</b>	<b>\$1,624,903</b>

**Reconciliations of non-GAAP financial measures**  
**(All figures are rounded. Totals may not add up due to rounding)**

**Fiscal year ("FY") 2009 adjusted diluted earnings per share from continuing operations ("EPS")**

Reported EPS	\$ 4.73
Tax benefit (1)	\$ (0.08)
Litigation charge (2)	<u>\$ 0.11</u>
Adjusted EPS	\$ 4.76

(1) Represents the tax benefit relating to various tax settlements in multiple jurisdictions.

(2) Represents the charge relating to the pending settlement with the direct purchaser plaintiffs (which includes BD's distributors) in the antitrust class actions.

**FY 2010 adjusted EPS**

Reported EPS	\$ 4.90
Tax charge (1)	<u>\$ 0.04</u>
Adjusted EPS	\$ 4.94

(1) Represents impact of non-cash charge related to health care reform impacting Medicare Part D reimbursements.

---

**Fourth quarter FY2010 foreign currency-neutral EPS growth**

	Reported Q4 FY2010	Reported Q4 FY2009	Change (\$)	Q4 FY2009 hedge gain	Q4 FY2010 impact of foreign currency translation	Q4 FY2010 hedge gain	Total favorable foreign currency impact	Foreign currency neutral growth (\$)	Foreign currency neutral growth (%)
EPS	\$ 1.24	\$ 1.20	\$0.04	(\$0.03)	\$ 0.02	\$ 0.03	0.02	\$ 0.02	1.7%

**FY2010 foreign currency-neutral EPS growth**

	FY2010	FY2009	Change (\$)	FY2009 foreign currency holding gain	FY2009 hedge gain	FY2010 impact of foreign currency translation	FY2010 hedge loss	Total unfavorable foreign currency impact	Foreign currency neutral growth (\$)	Foreign currency neutral growth (%)
Adjusted EPS	\$ 4.94	\$ 4.76	\$0.18	\$(0.09)	\$(0.26)	\$ 0.17	\$(0.08)	\$ (0.26)	\$ 0.44	9.2%